The observed difference was not statistically significant when interim analyses were accounted for.There were no statistically significant differences in adverse events between the arms.
The 7-year DFS rate was 81.3% in the placebo group and 84.7% in the letrozole group (HR, 0.85; 95% CI, 0.73â€“0.999;P= .048).
The observed difference was not statistically significant when interim analyses were accounted for.
There were no statistically significant differences in adverse events between the arms.
A phase III trial conducted by the IBCSG (SOLE[NCT00553410]) included 4,851 receptor-positive postmenopausal women who had completed 5 years of adjuvant therapy with an AI, a selective estrogen receptor (ER) modulator, or both.